Low-Dose Naltrexone as a Potential Healthspan-Enhancing Intervention in a Normative Aging Cohort: Changes in Quality of Life and Immune Health Metrics
Girish Harinath,
Sajad Zalzala,
Andy Nyquist
et al.
Abstract:Low-dose naltrexone (LDN) has been suggested to target the multiple hallmarks of aging and improve healthspan metrics in humans. However, to date, no studies have evaluated LDNs potential as a gerotherapeutic. We collected real-world data utilizing the short form 36 quality of life (QoL) assay, immune status questionnaire, and a patient-reported health assessment to evaluate the effectiveness of LDN for improving multiple healthspan metrics in a normative aging cohort still within their healthspan. Most partic… Show more
Set email alert for when this publication receives citations?
scite is a Brooklyn-based organization that helps researchers better discover and understand research articles through Smart Citations–citations that display the context of the citation and describe whether the article provides supporting or contrasting evidence. scite is used by students and researchers from around the world and is funded in part by the National Science Foundation and the National Institute on Drug Abuse of the National Institutes of Health.